lifestyle.thedailyhaze.com

Author: BioInvent International

BioInvent International AB Publishes Annual Report 2025

March 31, 2026
BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis

March 26, 2026
BioInvent International AB: Year-End Report January 1 – December 31, 2025

February 26, 2026
Invitation to Presentation of BioInvent’s Year-End Report 2025

February 26, 2026
BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting

February 23, 2026
BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer

January 5, 2026
BioInvent to Participate in Upcoming Investor Conference

December 20, 2025
BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025

December 8, 2025